Bezalip 200 mg Tablets
PDF Leaflet Revision Date: 8 December 2017
Clinical Summary
Quick overview from the medicine insert
Indication
Primary and secondary hyperlipidaemias.
Dosage (summary)
200 mg 2-3 times daily or 400 mg once daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated during pregnancy and lactation.
Key Drug Interactions
- Cholestyramine
- Oral anticoagulants
- Sulphonylureas
- Insulin
- HMG-CoA reductase inhibitors
Contraindications
- Hypersensitivity to bezafibrate
- Liver dysfunction
- Gall-bladder diseases
- Dialysis patients
- Severe renal impairment
Common side effects
- Gastrointestinal disturbances
- Myopathy
- Rhabdomyolysis
- Dizziness
- Nausea
Counselling Points
- Take with meals
- Monitor lipid levels regularly
- Report muscle pain or weakness
Serious warnings
- Risk of rhabdomyolysis with statins
- Monitor renal function in patients on immunosuppressants
Important Disclaimer
The Bezalip 200 mg Tablets professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
